Key result
Atenolol cuts heart rate ~28% in ovine hyperdynamic sepsis without worsening hypotension or kidney injury.
Why the study?
Does atenolol alter cardiac and renal function and cytokine release in ovine hyperdynamic sepsis?
Does atenolol alter cardiac and renal function and cytokine release in ovine hyperdynamic sepsis?
Absolute Event Rate: 109% vs 152%
p-value: p=<0.001
In an ovine model of hyperdynamic sepsis, selective β1-adrenoceptor blockade with atenolol reduced cardiac output and heart rate without deleterious effects on blood pressure or renal function, and enhanced anti-inflammatory IL-10 release.
Atenolol may be hemodynamically safe in ovine hyperdynamic sepsis; leaves open whether β1-blockade improves outcomes in human septic shock.
INTRODUCTION: Activation of the sympathetic nervous system has beneficial cardiovascular effects in sepsis, but there is also evidence that sympatholytics have beneficial actions in sepsis. We therefore determined the effect of selective β1-adrenoceptor blockade on cardiac and renal function and cytokine release in ovine hyperdynamic sepsis. METHODS: Hyperdynamic sepsis was induced by infusion of live E. coli for 24 hours in nine conscious sheep instrumented with flow probes on the pulmonary and left renal artery. Cardiovascular and renal function and levels of plasma cytokines were determined in a control group and during selective β1-adrenoceptor blockade with atenolol (10 mg intravenous bolus then 0.125 mg/kg/h) from 8 to 24 hours of sepsis. RESULTS: Hyperdynamic sepsis was characterized by hypotension with increases in cardiac output (CO), heart rate (HR) and renal blood flow (RBF), and acute kidney injury. Atenolol caused sustained reductions in HR (P < 0.001) and CO (P < 0.001). Despite the lower CO the sepsis-induced fall in mean arterial pressure (MAP) was similar in both groups. The sepsis-induced increase in RBF, decrease in renal function and increase in arterial lactate were unaffected by atenolol. Sepsis increased plasma levels of tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and IL-10. Atenolol caused a further increase in IL-10, but did not affect levels of TNF-α or IL-6. CONCLUSIONS: In sepsis, selective β1-adrenoceptor blockade reduced CO, but not MAP. During sepsis, atenolol did not alter the development of acute kidney injury or the levels of pro-inflammatory cytokines, but enhanced the release of IL-10. Atenolol appears safe in sepsis, has no deleterious cardiovascular or renal effects, and has an anti-inflammatory effect.
No takes yet. Share an insight, caveat, or question.
Calzavacca et al. (2014) studied Hyperdynamic sepsis (n=9). Atenolol vs. No treatment was evaluated on Heart rate (p=<0.001). In an ovine model of hyperdynamic sepsis, atenolol significantly reduced heart rate and cardiac output (P < 0.001) without causing greater hypotension or worsening acute kidney injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: